Navigo Proteins

Executive Summary

Navigo Proteins is a German biotechnology company founded in 2015 and headquartered in Halle, specializing in proprietary protein engineering to develop custom scaffold protein-based affinity ligands. The company operates two complementary business lines: Precision Capturing® for downstream bioprocessing optimization, and Precision Targeting for creating next-generation Affilin®-based biotherapeutics. By leveraging its unique protein engineering platform, Navigo aims to address challenges in biopharmaceutical purification and therapeutic development, offering alternatives to traditional antibodies with improved stability, tissue penetration, and manufacturing efficiency. The company has built a diverse pipeline of Affilin drug candidates targeting oncology and inflammatory diseases, though it remains in early-stage development without disclosed funding rounds or commercial products.

Upcoming Catalysts (preview)

• Q3 2026Partnership or licensing deal for Affilin therapeutic program40% success
• Q3 2026Series A or B financing round closure60% success
• TBDPublication of preclinical data for lead Affilin candidate70% success